AKEBIA THERAPEUTICS INC (AKBA) Fundamental Analysis & Valuation

NASDAQ:AKBA • US00972D1054

Current stock price

1.38 USD
-0.03 (-2.13%)
At close:
1.3798 USD
0 (-0.01%)
After Hours:

This AKBA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. AKBA Profitability Analysis

1.1 Basic Checks

  • In the past year AKBA has reported negative net income.
  • In the past year AKBA had a positive cash flow from operations.
  • AKBA had negative earnings in each of the past 5 years.
  • In the past 5 years AKBA reported 4 times negative operating cash flow.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -1.42%, AKBA belongs to the top of the industry, outperforming 87.04% of the companies in the same industry.
  • AKBA has a Return On Equity of -16.39%. This is amongst the best in the industry. AKBA outperforms 83.37% of its industry peers.
  • AKBA has a Return On Invested Capital of 9.54%. This is amongst the best in the industry. AKBA outperforms 93.23% of its industry peers.
Industry RankSector Rank
ROA -1.42%
ROE -16.39%
ROIC 9.54%
ROA(3y)-18.12%
ROA(5y)-26.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • With an excellent Operating Margin value of 10.92%, AKBA belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • AKBA has a Gross Margin of 82.83%. This is amongst the best in the industry. AKBA outperforms 86.07% of its industry peers.
  • In the last couple of years the Gross Margin of AKBA has grown nicely.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 82.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.51%
GM growth 5Y8.51%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AKBA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AKBA is still creating some value.
  • AKBA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, AKBA has more shares outstanding
  • The debt/assets ratio for AKBA has been reduced compared to a year ago.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -4.47, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
  • AKBA has a Altman-Z score of -4.47. This is in the lower half of the industry: AKBA underperforms 61.32% of its industry peers.
  • The Debt to FCF ratio of AKBA is 3.23, which is a good value as it means it would take AKBA, 3.23 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.23, AKBA belongs to the best of the industry, outperforming 92.65% of the companies in the same industry.
  • AKBA has a Debt/Equity ratio of 5.40. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 5.40, AKBA is not doing good in the industry: 81.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 5.4
Debt/FCF 3.23
Altman-Z -4.47
ROIC/WACC1.15
WACC8.28%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.55 indicates that AKBA should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.55, AKBA is doing worse than 81.24% of the companies in the same industry.
  • AKBA has a Quick Ratio of 1.46. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.46, AKBA is doing worse than 81.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.46
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. AKBA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 93.94% over the past year.
  • AKBA shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.46%.
  • Measured over the past years, AKBA shows a decrease in Revenue. The Revenue has been decreasing by -4.32% on average per year.
EPS 1Y (TTM)93.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)47.46%
Revenue growth 3Y-6.88%
Revenue growth 5Y-4.32%
Sales Q2Q%23.92%

3.2 Future

  • The Earnings Per Share is expected to grow by 62.06% on average over the next years. This is a very strong growth
  • AKBA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.09% yearly.
EPS Next Y-295.25%
EPS Next 2Y-105.12%
EPS Next 3Y98.15%
EPS Next 5Y62.06%
Revenue Next Year0.95%
Revenue Next 2Y-8.27%
Revenue Next 3Y3.25%
Revenue Next 5Y13.09%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

3

4. AKBA Valuation Analysis

4.1 Price/Earnings Ratio

  • AKBA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AKBA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 -60

4.2 Price Multiples

  • 94.39% of the companies in the same industry are more expensive than AKBA, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AKBA indicates a rather cheap valuation: AKBA is cheaper than 99.23% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.17
EV/EBITDA 13.98
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • AKBA's earnings are expected to grow with 98.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.12%
EPS Next 3Y98.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AKBA Dividend Analysis

5.1 Amount

  • AKBA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKBA Fundamentals: All Metrics, Ratios and Statistics

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (4/2/2026, 8:07:38 PM)

After market: 1.3798 0 (-0.01%)

1.38

-0.03 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners45.37%
Inst Owner Change0%
Ins Owners4.17%
Ins Owner Change11.5%
Market Cap369.67M
Revenue(TTM)236.20M
Net Income(TTM)-5.34M
Analysts87.27
Price Target4.49 (225.36%)
Short Float %11.53%
Short Ratio8.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.96%
Min EPS beat(2)-96.08%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)67.32%
Min EPS beat(4)-96.08%
Max EPS beat(4)165.36%
EPS beat(8)4
Avg EPS beat(8)25.41%
EPS beat(12)7
Avg EPS beat(12)15.35%
EPS beat(16)9
Avg EPS beat(16)20.81%
Revenue beat(2)1
Avg Revenue beat(2)10.74%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)22.56%
Revenue beat(4)3
Avg Revenue beat(4)19.1%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)29.66%
Revenue beat(8)4
Avg Revenue beat(8)4.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.03%
Revenue beat(16)8
Avg Revenue beat(16)12.53%
PT rev (1m)-4.35%
PT rev (3m)-18.52%
EPS NQ rev (1m)-36.36%
EPS NQ rev (3m)-200%
EPS NY rev (1m)0%
EPS NY rev (3m)-168.89%
Revenue NQ rev (1m)-2.26%
Revenue NQ rev (3m)-12.43%
Revenue NY rev (1m)-1.87%
Revenue NY rev (3m)-21.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.57
P/FCF 6.17
P/OCF 5.44
P/B 11.34
P/tB N/A
EV/EBITDA 13.98
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.22
FCFY16.2%
OCF(TTM)0.25
OCFY18.39%
SpS0.88
BVpS0.12
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.42%
ROE -16.39%
ROCE 12.08%
ROIC 9.54%
ROICexc 70.81%
ROICexgc N/A
OM 10.92%
PM (TTM) N/A
GM 82.83%
FCFM 25.36%
ROA(3y)-18.12%
ROA(5y)-26.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.51%
GM growth 5Y8.51%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 5.4
Debt/FCF 3.23
Debt/EBITDA 6.51
Cap/Depr 638.14%
Cap/Sales 3.43%
Interest Coverage 4.24
Cash Conversion 251.19%
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.46
Altman-Z -4.47
F-Score5
WACC8.28%
ROIC/WACC1.15
Cap/Depr(3y)212.74%
Cap/Depr(5y)127.74%
Cap/Sales(3y)1.15%
Cap/Sales(5y)0.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-295.25%
EPS Next 2Y-105.12%
EPS Next 3Y98.15%
EPS Next 5Y62.06%
Revenue 1Y (TTM)47.46%
Revenue growth 3Y-6.88%
Revenue growth 5Y-4.32%
Sales Q2Q%23.92%
Revenue Next Year0.95%
Revenue Next 2Y-8.27%
Revenue Next 3Y3.25%
Revenue Next 5Y13.09%
EBIT growth 1Y155.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y247.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y267.23%
OCF growth 3YN/A
OCF growth 5YN/A

AKEBIA THERAPEUTICS INC / AKBA Fundamental Analysis FAQ

What is the fundamental rating for AKBA stock?

ChartMill assigns a fundamental rating of 4 / 10 to AKBA.


What is the valuation status for AKBA stock?

ChartMill assigns a valuation rating of 3 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Overvalued.


Can you provide the profitability details for AKEBIA THERAPEUTICS INC?

AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 5 / 10.


Can you provide the financial health for AKBA stock?

The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 3 / 10.


Can you provide the expected EPS growth for AKBA stock?

The Earnings per Share (EPS) of AKEBIA THERAPEUTICS INC (AKBA) is expected to decline by -295.25% in the next year.